Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

Background & Aims. This paper presents the results of the observational study of ibrutinib in patients with chronic lymphocytic leukemia (CLL), conducted in SP Botkin Municipal Clinical Hospital. The main objective was the analysis of complications of ibrutinib and identification of factors, inf...

Full description

Bibliographic Details

Published in:	Клиническая онкогематология
Main Authors:	EA Nikitin, EA Dmitrieva, MA Panteleev, EI Emelina, VL Ivanova, YuB Kochkareva, EG Arshanskaya, IE Lazarev, EE Markova, LA Mukha, NG Novitskaya, MM Pankrashkina, VV Glazunova, AV Shubina, SA Chernysh, NK Khuazheva, EV Naumova, SA Lugovskaya, ME Pochtar’, TN Obukhova, OYu Vinogradova, GE Gendlin, VV Ptushkin
Format:	Article
Language:	Russian
Published:	Practical Medicine Publishing House 2017-07-01
Subjects:	chronic lymphocytic leukemia del 17p TP53 refractory CLL ibrutinib bleeding atrial fibrillation
Online Access:	http://bloodjournal.ru/wp-content/uploads/2017/09/1.pdf